MSH2 and neuroendocrine carcinoma: In 2022, a 49-year-old female was identified carrying an MSH2 missense mutation c.1808A>T, while she successively had EC, lymphoma, colonic cancer, gastric adenocarcinoma, and neuroendocrine carcinoma (IHC on NEN showed reduced expression of the MSH2 protein) [66].